Accès ouvert déclaré
2022
article
Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
Borja Quiroga, María José Soler, Alberto Ortíz, Carlos Jesús Jaravaca Mantecón, Nathasha Nava Pérez, Marta Serra Martín, Yurika Sato, Antonio Franco, Diana Flor Pazmiño Zambrano, Rafael Lucena Valverde, Mayra Ortega Díaz, Carmen Calderón González, Juan Manuel Cazorla López, Mónica Pereira, Emilio González Parra, Ana Sánchez Horrillo, Sánchez González, Néstor Toapanta, Secundino Cigarrán Guldris, Rosa Sánchez Hernández, Soledad Pizarro Sánchez, María Muñiz Rincón, Nuria Garcı́a-Fernández, Natalia Blanco Castro, Rocío Collantes Mateo, Manuel Augusto Quiroz Morales, Beatriz Escamilla-Cabrera, Isabel Berdud Godoy, Beatriz Gil-Casares Casanova, Alba Leyva, José Antonio Muñoz Rojas, Ron T. Gansevoort, Patricia de Sequera, Marta Puerta Carretero, Daniel Gaitán Tocora, Ma Teresa Jaldo Rodríguez, Tamar Talaván Zanón, Esther Rodriguez Suárez, Alfredo José Sáenz Santolaya, Raquel Cerrajero Calero, Patricia Arribas Cobo, Patricia Muñoz Ramos, Carolina Gracia-Iguacel, Catalina Martín-Cleary, Jinny Sánchez-Rodríguez, Ana Ramos-Verde, Yohana Gil Giraldo, Pablo Ruano Suárez, Antonio Fernández Perpén, Andrés Fernández-Ramos, Laura Salanova Villanueva, Alejandra Cortiñas, Pablo A Díez Arias, Alicia Cabrera Cárdenas, Antonio de Santos, Almudena Hernández Núñez, Guillermina Barril, Raquel Repollet, Francesc Moreso, María Azancot, Natália Ramos, Oriol Bestard, Ignacio Cidraque, Sheila Bermejo, Irene Agraz, Oreto Prat, Carlota Medina, Emma Pardo, A. Sáiz, Nicolás Menéndez Granados, María Jesús Corton Cabo, Walter López Alarcón, Simona Alexandru, Laura García Puente Suarez, Saúl Pampa Saico, Marisol Poma Tapia, Laura Rodríguez Osorio, Rocío Zamora, Paloma Leticia Martin Moreno, Noelia Ania González, Ana Sabalza Ortiz, María Nieves Bastida Iñarrea, Teresa Garcı́a, Carlos F. Narváez, Cristhian Orellana, José Luis Pizarro León, Manuel Antonio Martínez García, Benaldina García Jiménez, Juan de Dios Ramiro Moya, Diana López Espinosa, Alejandro Jiménez Herrador, Manuel Navarro Zurita, Leonardo Díaz Álvarez, Álvaro González Martínez, Sandra Báez Arroyo, Raquel Reina Fernández, Marlyn Janella Suárez Vargas, Rocío Calurano Casero, Gustavo Useche, Carmen Santamaría de Miguel, Ángel Palacios, Brenda Henningsmeyer, Esther Orero Calve, José Lacueva Moya, Sandra Castellano Gash, Lara Ruíz Martínez, Virginia Lopez De La Manzanara Perez, Marta Calvo Arevalo, José Antonio Herrero Calvo, Mercedes Salgueira, Nuria Aresté-Fosalba, María de los Ángeles Rodríguez Gázquez, Rocío Collantes, Ana Isabel Ortega Martínez, María Jesús Moyano, Elena Jiménez Víbora, Aurelio Pastor Rodríguez Hernández, María Sagrario García Rebollo, Juana Margarita Rufino Hernández, Esther Torres Aguilera, Rolando Tello Alea, Margie Soledad Del Rosario Saldaña, Ana María Urraca de la Pisa, Lidia Sendino Monzon, Karina Ampuero Anachuri, Esther Hernández Garcia, Victoria Oviedo Gómez, Ignacio Manzur Cavalotti, Itziar Navarro Zorita, Sol Otero López, Sara Outon González, Carlos Soto Montañez, Manuel Ramírez de Arellano Serna, Luis Guirado Perich, Eva Cotilla de la Rosa
16Citations signalées, ce qui n’est pas une note de qualité
20Institutions déclarées
2Pays d’affiliation déclarés
Rattachement africain : es, nl.
Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT Background Patients on hemodialysis are at high-risk for complications derived from coronavirus disease 2019 (COVID-19). The present analysis evaluated the impact of a booster vaccine dose and breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on humoral immunity 3 months after the booster dose. Methods This is a multicentric and prospective study assessing immunoglobulin G anti-Spike antibodies 6 and 9 months after initial SARS-CoV-2 vaccination in patients on hemodialysis that had also received a booster dose before the 6-month assessment (early booster) or between the 6- and 9-month assessments (late booster). The impact of breakthrough infections, type of vaccine, time from the booster and clinical variables were assessed. Results A total of 711 patients [67% male, median age (range) 67 (20–89) years] were included. Of these, 545 (77%) received an early booster and the rest a late booster. At 6 months, 64 (9%) patients had negative anti-Spike antibody titers (3% of early booster and 29% of late booster patients, P = .001). At 9 months, 91% of patients with 6-month negative response had seroconverted and there were no differences in residual prevalence of negative humoral response between early and late booster patients (0.9% vs 0.6%, P = .693). During follow-up, 35 patients (5%) developed breakthrough SARS-CoV-2 infection. Antibody titers at 9 months were independently associated with mRNA-1273 booster (P = .001), lower time from booster (P = .043) and past breakthrough SARS-CoV-2 infection (P < .001). Conclusions In hemodialysis patients, higher titers of anti-Spike antibodies at 9 months were associated with mRNA-1273 booster, lower time from booster and past breakthrough SARS-CoV-2 infection.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
- Date Crossref
- 26/07/2022
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
SARS-CoV-2 and COVID-19 ResearchHeparin-Induced Thrombocytopenia and ThrombosisComplement system in diseases